PBSV · Pharma-Bio Serv, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.29M | - | $1.96M | $2.42M | $2.47M | - | $2.42M | $2.38M | $2.38M | - |
| Cost of Revenue | $1.57M | - | $1.39M | $1.60M | $1.70M | - | $1.78M | $1.76M | $1.84M | - |
| Gross Profit | $722.4K | - | $574.3K | $818.7K | $768.1K | - | $635.4K | $618.5K | $535.6K | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $816.9K | - | $888.1K | $917.0K | $860.3K | - | $1.02M | $931.9K | $973.9K | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $14.8K | - | $15.7K | $18.9K | $9.4K | - | $4.6K | $5.5K | $16.1K | - |
| Operating Income | ($94.5K) | - | ($313.9K) | ($98.3K) | ($92.2K) | - | ($381.8K) | ($313.4K) | ($438.3K) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $3.6K | - | $4.8K | $5.5K | $1.1K | - | $19.0K | $21.2K | $12.9K | - |
| Net Income | $32.9K | - | ($204.3K) | $95.4K | $8.5K | - | ($309.2K) | ($213.8K) | ($270.7K) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | $0.00 | - | $0.01 | ($0.01) | ($0.01) | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.76M | $3.38M | $3.96M | $2.09M | $7.31M | $6.77M | $6.52M | $3.51M | $6.41M | $10.45M |
| Accounts Receivable | $2.65M | $2.36M | $2.02M | $2.68M | $2.68M | $2.51M | $2.60M | $2.61M | $2.41M | $3.94M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $13.32M | $13.39M | $13.16M | $13.42M | $15.53M | $15.70M | $15.94M | $16.51M | $18.78M | $19.40M |
| Total Assets | $13.55M | $13.65M | $13.59M | $13.90M | $16.08M | $16.29M | $16.32M | $16.92M | $19.23M | $19.90M |
| Current Liabilities | $3.31M | $1.74M | $1.66M | $1.78M | $3.42M | $1.89M | $1.90M | $2.20M | $3.68M | $2.15M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.31M | $1.74M | $1.66M | $1.78M | $4.08M | $2.58M | $2.63M | $2.97M | $5.07M | $3.78M |
| Stockholders' Equity | $10.24M | $11.91M | $11.93M | $12.12M | $12.00M | $13.72M | $13.69M | $13.95M | $14.16M | $16.13M |
| Retained Earnings | $8.85M | $10.53M | $10.53M | $10.74M | $10.64M | $12.35M | $12.34M | $12.65M | $12.86M | $14.85M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($390.1K) | - | $236.5K | ($301.6K) | ($429.5K) | - | ($670.3K) | ($700.7K) | $725.9K | - |
| Investing Cash Flow | $2.77M | - | $1.63M | ($3.23M) | $988.3K | - | $3.69M | ($458.9K) | ($4.76M) | - |
| Financing Cash Flow | ($1.7K) | - | ($5.0K) | ($1.74M) | $0 | - | ($1.7K) | ($1.72M) | ($7.2K) | - |
| CapEx | $2.4K | - | $2.0K | $4.3K | $0 | - | $1.9K | $0 | $820 | - |
| Free Cash Flow | ($392.6K) | - | $234.5K | ($305.8K) | ($429.5K) | - | ($672.2K) | ($700.7K) | $725.1K | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 31.5% | - | 29.3% | 33.9% | 31.1% | - | 26.3% | 26.0% | 22.5% | - |
| Operating margin | -4.1% | - | -16.0% | -4.1% | -3.7% | - | -15.8% | -13.2% | -18.4% | - |
| EBITDA margin | -3.5% | - | -15.2% | -3.3% | -3.3% | - | -15.6% | -12.9% | -17.7% | - |
| Net margin | 1.4% | - | -10.4% | 3.9% | 0.3% | - | -12.8% | -9.0% | -11.4% | - |
| Free cash flow margin | -17.1% | - | 11.9% | -12.7% | -17.4% | - | -27.8% | -29.5% | 30.5% | - |
| FCF / Net income | -11.95 | - | -1.15 | -3.21 | -50.31 | - | 2.17 | 3.28 | -2.68 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 35.6% | - | 45.2% | 37.9% | 34.8% | - | 42.1% | 39.2% | 40.9% | - |
| Effective tax rate | 9.9% | - | - | 5.5% | 11.6% | - | - | - | - | - |
| Return on assets | 0.2% | - | -1.5% | 0.7% | 0.1% | - | -1.9% | -1.3% | -1.4% | - |
| Return on equity | 0.3% | - | -1.7% | 0.8% | 0.1% | - | -2.3% | -1.5% | -1.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.03 | 7.70 | 7.93 | 7.54 | 4.54 | 8.32 | 8.39 | 7.52 | 5.10 | 9.01 |
| Quick ratio | 4.03 | 7.70 | 7.93 | 7.54 | 4.54 | 8.32 | 8.39 | 7.52 | 5.10 | 9.01 |
| Cash ratio | 1.74 | 1.94 | 2.39 | 1.18 | 2.14 | 3.59 | 3.43 | 1.60 | 1.74 | 4.85 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.32 | 1.15 | 1.14 | 1.15 | 1.34 | 1.19 | 1.19 | 1.21 | 1.36 | 1.23 |
| Liabilities / Assets | 0.24 | 0.13 | 0.12 | 0.13 | 0.25 | 0.16 | 0.16 | 0.18 | 0.26 | 0.19 |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | - | 0.14 | 0.17 | 0.15 | - | 0.15 | 0.14 | 0.12 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 422d | - | 375d | 405d | 396d | - | 392d | 401d | 369d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -7.1% | - | -18.8% | 1.7% | 3.8% | - | -47.2% | -47.9% | -43.8% | - |
| Revenue CAGR (3y) | -18.5% | - | -25.6% | -21.7% | -21.0% | - | -21.4% | -22.2% | -19.1% | - |
| Revenue CAGR (5y) | -12.6% | - | -20.7% | -15.6% | -11.7% | - | -13.4% | -14.3% | -12.2% | - |
| Gross profit growth (YoY) | -6.0% | - | -9.6% | 32.4% | 43.4% | - | -59.0% | -54.1% | -56.8% | - |
| Operating income growth (YoY) | -2.5% | - | 17.8% | 68.6% | 79.0% | - | - | - | - | - |
| Net income growth (YoY) | 285.0% | - | 33.9% | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 8.6% | - | - | 56.4% | - | - | - | -179.3% | -16.4% | - |
| FCF CAGR (5y) | - | - | -28.0% | - | - | - | - | - | - | - |
| Book value growth (YoY) | -14.6% | -13.1% | -12.9% | -13.1% | -15.3% | -15.0% | -15.4% | -11.0% | -16.7% | -2.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-10-31.
Geographic
$9.00M totalPuerto Rico Consulting$4.64M · 51.5%
United States Consulting$2.62M · 29.1%
Europe Consulting$1.73M · 19.2%
Other Segment$16.7K · 0.2%
Peer comparison
Same SIC group: Services-Management Consulting Services
Comparing Pharma-Bio Serv against the 5 most active filers in the same SIC group.